一文汇总,2023 ASCO乳腺癌领域中国之声

作者:肿瘤瞭望   日期:2023/5/10 14:12:56  浏览量:5608

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

一年一度的临床肿瘤学界奥林匹克盛会——美国临床肿瘤学会(ASCO)年会将于当地时间6月2~6日在芝加哥举行。日前,ASCO会议官网公布了此次年会的日程和摘要题目。肿瘤瞭望将乳腺癌领域入选大会展示中国专家投稿文章进行了汇总,与读者分享(排名不分先后,如有遗漏请后台留言补充)。

编者按:一年一度的临床肿瘤学界奥林匹克盛会——美国临床肿瘤学会(ASCO)年会将于当地时间6月2~6日在芝加哥举行。日前,ASCO会议官网公布了此次年会的日程和摘要题目。肿瘤瞭望将乳腺癌领域入选大会展示中国专家投稿文章进行了汇总,与读者分享(排名不分先后,如有遗漏请后台留言补充)。
 
6月4日——Rapid Abstract Session(Breast Cancer)
 
摘要号:LBA1013
TORCHLIGHT:A randomized,double-blind,phase III trial of toripalimab versus placebo,in combination with nab-paclitaxel(nab-P)for patients with metastatic or recurrent triple-negative breast cancer(TNBC).
TORCHLIGHT:一项特瑞普利单抗对比安慰剂联合白蛋白紫杉醇(nab-P)用于转移性或复发性三阴性乳腺癌(TNBC)患者的随机、双盲、Ⅲ期试验
讲者:江泽飞(解放军总医院第五医学中心)

6月4日——Poster Session
 
▌Breast Cancer—Local/Regional/Adjuvant
 
摘要号:526|Poster Bd#:356
Differences of prediction performances by multigene assays in patients with breast cancer with distinct genetic backgrounds.
多基因检测在具有不同遗传背景的乳腺癌患者中的预测性能差异
讲者:邢飞(中国医科大学附属盛京医院)
 
摘要号:528|Poster Bd#:358
Differential benefit of capecitabine-based chemotherapy among TNBC subtypes in the context of the CBCSG010 study.
在CBCSG010研究背景下,基于卡培他滨的化疗在TNBC亚型中的差异获益
讲者:李俊杰(复旦大学附属肿瘤医院)
 
摘要号:550|Poster Bd#:380
Cardiac safety and efficacy for patients with early-stage breast cancer treated with pegylated liposomal doxorubicin(PLD)or doxorubicin.
接受PLD或多柔比星治疗的早期乳腺癌患者的心脏安全性和有效性
讲者:汤立晨(复旦大学附属肿瘤医院)
 
摘要号:558|Poster Bd#:388
Decision value of the circulating tumor DNA on the adjuvant anti-Her2 regimens in patients with Her2-positive breast cancer treated with neoadjuvant therapy.
循环肿瘤DNA对接受新辅助治疗的HER2阳性乳腺癌患者辅助抗HER2方案的决策价值
讲者:Po-Han Lin(国立台湾大学医院)
 
摘要号:569|Poster Bd#:399
ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis.
ERBB2 mRNA表达与HER2低表达/阴性乳腺癌预后的关系
讲者:刘月平(河北医科大学第四医院)
 
摘要号:593|Poster Bd#:423
Taxane combined with lobaplatin or anthracycline for neoadjuvant treatment of triple-negative breast cancer:A single-center,randomized,controlled,phase-II clinical study.
一项单中心、随机、对照、Ⅱ期临床研究:紫杉烷联合洛铂或蒽环类药物用于三阴性乳腺癌新辅助治疗
讲者:Cheng Wang(陆军军医大学西南医院)
 
摘要号:594|Poster Bd#:424
Use of PLR and NLR to evaluate the efficacy and prognosis of neoadjuvant chemotherapy with lobaplatin in triple-negative breast cancer.
利用PLR和NLR评估洛铂新辅助化疗治疗三阴性乳腺癌的疗效和预后。
讲者:Cheng Wang(陆军军医大学西南医院)
 
摘要号:599|Poster Bd#:429
Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy:A multicenter,retrospective study.
一项多中心、回顾性研究:基于纵向MRI的融合新模型预测乳腺癌新辅助化疗病理完全缓解
讲者:王坤(广东省人民医院)
 
摘要号:602|Poster Bd#:432
Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin followed by adjuvant tislelizumab in patients with early triple-negative breast cancer.
早期三阴性乳腺癌患者接受替雷利珠单抗+白蛋白结合型紫杉醇和卡铂新辅助治疗后继续接受替雷利珠单抗辅助治疗。
讲者:江泽飞(解放军总医院第五医学中心)
 
摘要号:607|Poster Bd#:437
A prospective,phase II,neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor–positive,HER2-negative breast cancer:FINEST study.
FINEST研究:一项基于激素受体阳性、HER2阴性乳腺癌化疗敏感性的前瞻性Ⅱ期新辅助临床研究
讲者:陈力(复旦大学附属肿瘤医院)
 
6月4日——Poster Session
 
▌Breast Cancer—Metastatic
 
摘要号:1027|Poster Bd#:248
Clinical features,genomic landscapes,and survival outcomes of HER2-low breast cancer.
HER2低表达乳腺癌患者的临床特征、基因组特征和生存结局
讲者:Jin Juan(复旦大学附属肿瘤医院)
 
摘要号:1034|Poster Bd#:255
Negative estrogen receptor expression assessed by 18F-FES PET in metastatic breast cancer with ER-positive primary tumor.
18F-FES PET评估原发肿瘤为ER阳性雌激素受体表达阴性的转移性乳腺癌
讲者:王碧芸(复旦大学附属肿瘤医院)
 
摘要号:1040|Poster Bd#:261
Preclinical and early clinical data of ZN-1041,a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases.
临床前和早期临床数据显示,ZN-1041是最佳的BBB穿透性HER2抑制剂,用于治疗CNS转移的乳腺癌患者。
讲者:马飞(中国医学科学院肿瘤医院)
 
摘要号:1042|Poster Bd#:263
Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer:Final results from the phase 2 ICU trial.
抗HER2抗体inetetamab联合卡瑞利珠单抗和优替德隆治疗既往经治的HER2阳性转移性乳腺癌:2期ICU试验的最终结果
讲者:律慧敏(河南省肿瘤医院)
 
摘要号:1044|Poster Bd#:265
Zanidatamab(zani),a HER2-targeted bispecific antibody,in combination with docetaxel as first-line therapy(1L)for patients(pts)with advanced HER2-positive breast cancer(BC):Updated results from a phase 1b/2 study.
1b/2期研究的最新结果:靶向HER2的双特异抗体Zanidatamab联合多西他赛作为晚期HER2阳性乳腺癌(BC)患者的一线治疗(1L)。
讲者:王晓稼(浙江省肿瘤医院)
 
摘要号:1045|Poster Bd#:266
Updated results from a phase 2 study on dalpiciclib and pyrotinib,a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer(DAP-HER-01).
2期DAP-HER-01研究的最新结果:dalpiciclib联合pyrotinib治疗HER2阳性晚期乳腺癌的双口服无化疗方案。
讲者:闫敏(河南省肿瘤医院)
 
摘要号:1046|Poster Bd#:267
PLEASURABLE:Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy(ET)in women with dual-receptor positive(ER+/HER2+)metastatic breast cancer(MBC).
Ⅱ期PLEASURABLE研究结果和生物标志物分析:达尔西利联合吡咯替尼和内分泌治疗(ET)ER+/HER2+转移性乳腺癌(MBC)
讲者:张剑(复旦大学附属肿瘤医院)
 
摘要号:1048|Poster Bd#:269
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases:3-year follow-up results from the phase 2 PERMEATE trial.
2期PERMEATE试验3年随访结果:吡咯替尼联合卡培他滨治疗HER2阳性转移性乳腺癌和脑转移患者
讲者:闫敏(河南省肿瘤医院)
 
摘要号:1072|Poster Bd#:293
A multicenter,single-arm,open-label trial of birociclib,a CDK4/6 inhibitor,as a single agent,in patients with refractory HR+/HER2-metastatic breast cancer.
一项多中心、单臂、开放标签的试验:CDK4/6抑制剂birociclib单药治疗难治性HR+/HER2-转移性乳腺癌
讲者:王佳玉(中国医学科学院肿瘤医院)
 
摘要号:1085|Poster Bd#:306
Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer:Binding of YAP.
染色质重塑分子ARID1A对三阴性乳腺癌转移异质性的影响:YAP的结合
讲者:Ye Wang(复旦大学附属肿瘤医院)
 
摘要号:1086|Poster Bd#:307
The overall survival analysis of FUTURE-C-PLUS:Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced,immunomodulatory triple-negative breast cancer—An open-label,single-arm,phase 2 trial.
FUTURE-C-PLUS研究总生存期分析:法米替尼联合卡瑞利珠单抗和白蛋白结合型紫杉醇作为晚期免疫调节型三阴性乳腺癌的一线治疗
讲者:陈力(复旦大学附属肿瘤医院)
 
摘要号:1088|Poster Bd#:309
ARID1A deficiency in triple-negative breast cancer induces adaptive immune resistance and sensitivity to immune checkpoint inhibitors.
三阴性乳腺癌的ARID1A缺陷诱导适应性免疫抵抗和对免疫检查点抑制剂的敏感性
讲者:Margaret Chen(复旦大学附属肿瘤医院)
 
摘要号:1100|Poster Bd#:321
Preliminary results from a first-in-human study of ESG401,a trophoblast cell-surface antigen 2(TROP2)antibody drug conjugate(ADC),in patients with locally advanced/metastatic solid tumors.
ESG401是滋养层细胞表面抗原2(TROP2)抗体药物偶联物(ADC),在局部晚期/转移性实体瘤患者中进行的第一项人体研究的初步结果。
讲者:马飞(中国医学科学院肿瘤医院)
 
6月5日Poster Discussion Session
 
▌Breast Cancer—Metastatic
 
摘要号:1017|Poster Bd#:238
LEONARDA-1:Phase III randomized study of lerociclib plus fulvestrant in patients with HR+,HER2-locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.
LEONARDA-1:Ⅲ期随机对照研究,lerociclib联合氟维司群治疗既往内分泌治疗进展的HR+、HER2-局部晚期或转移性乳腺癌患者。
讲者:徐兵河(中国医学科学院肿瘤医院)

摘要号:1021|Poster Bd#:242
HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort.
一项大规模队列研究中原发性和复发/转移性乳腺癌HER2低表达状态的不一致性
讲者:林明曦(复旦大学附属肿瘤医院)

版面编辑:张靖璇  责任编辑:聂会珍

本内容仅供医学专业人士参考


乳腺癌

分享到: 更多